Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry Nolan

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Vaccine|September 17, 2014
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young childrenTerry Nolan, Lulu Bravo, Ana Ceballos, et al.
Vaccine|March 6, 2018
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised studyClare L Cutland, Terry Nolan, Scott A Halperin, et al.
JAMA|December 23, 2009
Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trialTerry Nolan, Jodie McVernon, Maryanne Skeljo, et al.
Pediatrics|June 1, 2011
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infantsKristina A Bryant, Gary S Marshall, Colin D Marchant, et al.
The Pediatric Infectious Disease Journal|October 20, 2012
Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlersRobert Booy, Peter Richmond, Terry Nolan, et al.
NPJ Vaccines|July 6, 2026
Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysisPavo Marijic, Katarzyna Jamróz-Dolińska, Wojciech Margas, et al.
Vaccine|April 7, 2015
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trialJosefina B Cadorna-Carlos, Terry Nolan, Charissa Fay Borja-Tabora, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Vaccine|September 20, 2008
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and childrenTerry Nolan, Peter C Richmond, Neil T Formica, et al.
Vaccine|January 30, 2019
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccineTerry Nolan, Maria Elena Santolaya, Ferdinandus de Looze, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Vaccine|September 17, 2014
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young childrenTerry Nolan, Lulu Bravo, Ana Ceballos, et al.
Vaccine|March 6, 2018
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised studyClare L Cutland, Terry Nolan, Scott A Halperin, et al.
JAMA|December 23, 2009
Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trialTerry Nolan, Jodie McVernon, Maryanne Skeljo, et al.
Pediatrics|June 1, 2011
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infantsKristina A Bryant, Gary S Marshall, Colin D Marchant, et al.
The Pediatric Infectious Disease Journal|October 20, 2012
Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlersRobert Booy, Peter Richmond, Terry Nolan, et al.
NPJ Vaccines|July 6, 2026
Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysisPavo Marijic, Katarzyna Jamróz-Dolińska, Wojciech Margas, et al.
Vaccine|April 7, 2015
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trialJosefina B Cadorna-Carlos, Terry Nolan, Charissa Fay Borja-Tabora, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Vaccine|September 20, 2008
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and childrenTerry Nolan, Peter C Richmond, Neil T Formica, et al.
Vaccine|January 30, 2019
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccineTerry Nolan, Maria Elena Santolaya, Ferdinandus de Looze, et al.
Pageof 10